KR102785140B1 - 신규 항-cd3엡실론 항체 - Google Patents

신규 항-cd3엡실론 항체 Download PDF

Info

Publication number
KR102785140B1
KR102785140B1 KR1020207011016A KR20207011016A KR102785140B1 KR 102785140 B1 KR102785140 B1 KR 102785140B1 KR 1020207011016 A KR1020207011016 A KR 1020207011016A KR 20207011016 A KR20207011016 A KR 20207011016A KR 102785140 B1 KR102785140 B1 KR 102785140B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
ser
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207011016A
Other languages
English (en)
Korean (ko)
Other versions
KR20200055052A (ko
Inventor
징 리
친 메이
Original Assignee
우시 바이올로직스 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우시 바이올로직스 아일랜드 리미티드 filed Critical 우시 바이올로직스 아일랜드 리미티드
Priority to KR1020257008876A priority Critical patent/KR20250046337A/ko
Publication of KR20200055052A publication Critical patent/KR20200055052A/ko
Application granted granted Critical
Publication of KR102785140B1 publication Critical patent/KR102785140B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207011016A 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체 Active KR102785140B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257008876A KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/102622 2017-09-21
CN2017102622 2017-09-21
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257008876A Division KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Publications (2)

Publication Number Publication Date
KR20200055052A KR20200055052A (ko) 2020-05-20
KR102785140B1 true KR102785140B1 (ko) 2025-03-25

Family

ID=65811028

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207011016A Active KR102785140B1 (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체
KR1020257008876A Pending KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257008876A Pending KR20250046337A (ko) 2017-09-21 2018-09-20 신규 항-cd3엡실론 항체

Country Status (18)

Country Link
US (3) US11440962B2 (enExample)
EP (1) EP3684806A4 (enExample)
JP (2) JP7305624B2 (enExample)
KR (2) KR102785140B1 (enExample)
CN (2) CN111108119B (enExample)
AU (2) AU2018336519B2 (enExample)
BR (1) BR112020004992A2 (enExample)
CA (1) CA3074130A1 (enExample)
EA (1) EA202090800A1 (enExample)
IL (2) IL273393B1 (enExample)
MX (1) MX2020003087A (enExample)
MY (1) MY199530A (enExample)
PH (1) PH12020550078A1 (enExample)
SA (2) SA523440043B1 (enExample)
SG (1) SG11202001358RA (enExample)
TW (2) TWI879275B (enExample)
WO (1) WO2019057099A1 (enExample)
ZA (1) ZA202001314B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50188A (fr) 2017-09-22 2021-06-02 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques bispécifiques
WO2019057124A1 (en) * 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. NEW BISPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES
WO2020247929A1 (en) 2019-06-07 2020-12-10 Adimab, Llc High affinity anti-cd3 antibodies, and methods for their generation and use
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
BR112022018088A2 (pt) 2020-03-12 2023-01-17 Immune Onc Therapeutics Inc Novos anticorpos anti-lilrb4 e produtos derivados
CA3184189A1 (en) * 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
WO2022022464A1 (zh) * 2020-07-27 2022-02-03 正大天晴药业集团股份有限公司 新型双特异性抗cd3/cd20多肽复合物配制剂
US11795224B2 (en) 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
WO2023173258A1 (zh) * 2022-03-14 2023-09-21 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
KR20250113537A (ko) * 2022-10-25 2025-07-25 아블렉시스, 엘엘씨 항-cd3 항체
EP4623007A1 (en) 2022-11-24 2025-10-01 WuXi Biologics Ireland Limited Psma antibodies and uses thereof
CN121164642B (zh) * 2025-09-26 2026-05-12 广州医太通生物科技有限公司 一种用于微生物检测的试剂盒及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CN1169953C (zh) * 1999-11-30 2004-10-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
SG10201808730VA (en) * 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
EP4180458A1 (en) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
US8569450B2 (en) * 2010-03-03 2013-10-29 Health Research Inc. CD3 epsilon immunogens and antibodies
CN104098698B (zh) * 2013-04-08 2019-04-05 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
EP3004164A1 (en) * 2013-05-28 2016-04-13 Numab AG Novel antibodies
MX379030B (es) * 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
RU2016151235A (ru) * 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
CA2963692A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
EP3812398A3 (en) * 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123

Also Published As

Publication number Publication date
BR112020004992A2 (pt) 2020-10-06
TWI879275B (zh) 2025-04-01
JP2020534830A (ja) 2020-12-03
KR20250046337A (ko) 2025-04-02
US20200299384A1 (en) 2020-09-24
TW202428617A (zh) 2024-07-16
EP3684806A1 (en) 2020-07-29
MX2020003087A (es) 2020-08-17
TWI820041B (zh) 2023-11-01
WO2019057099A1 (en) 2019-03-28
SA523440043B1 (ar) 2024-02-08
NZ762170A (en) 2023-10-27
CN111108119A (zh) 2020-05-05
JP7305624B2 (ja) 2023-07-10
IL273393B1 (en) 2026-02-01
AU2025201457A1 (en) 2025-03-20
EP3684806A4 (en) 2021-09-22
CN115991777A (zh) 2023-04-21
US12485298B2 (en) 2025-12-02
US20230192850A1 (en) 2023-06-22
AU2018336519B2 (en) 2024-12-19
US11440962B2 (en) 2022-09-13
MY199530A (en) 2023-11-03
KR20200055052A (ko) 2020-05-20
SA520411577B1 (ar) 2024-02-08
CA3074130A1 (en) 2019-03-28
EA202090800A1 (ru) 2020-08-11
JP7737193B2 (ja) 2025-09-10
PH12020550078A1 (en) 2022-07-18
CN111108119B (zh) 2022-11-15
IL273393A (en) 2020-05-31
ZA202001314B (en) 2021-08-25
AU2018336519A1 (en) 2020-03-05
TW201922787A (zh) 2019-06-16
US20260116974A1 (en) 2026-04-30
JP2023126851A (ja) 2023-09-12
IL325604A (en) 2026-02-01
SG11202001358RA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
US12485298B2 (en) Anti-CD3epsilon antibodies
CN112218892B (zh) 新型抗ctla-4抗体多肽
US20240052052A1 (en) Novel anti-cd24 antibodies
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
KR20240025513A (ko) 신규 항-cd276 항체 및 이의 용도
US20250368734A1 (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
JP2025509336A (ja) 新規抗ｃｄ３抗体およびその使用
KR20200055758A (ko) 신규 항-cd19 항체
US12486325B2 (en) Anti-CD3epsilon antibodies
IL325173A (en) New antibodies targeting CD3 and another target and their uses
EA042856B1 (ru) Новые анти-cd3-эпсилон антитела
TW202413417A (zh) 新穎抗ｃｄ３抗體及其用途
EA051013B1 (ru) Новые анти-cd3эпсилон антитела
EA052500B1 (ru) Новые антитела против cd24
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 32

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 30